Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
|Videos|December 22, 2021
Helping Oncology Patients Through Holistic Wellness
Holistic wellness and helping patients manage the toxins in their outside life are just a few of the focuses at Wobbly Arrow Wellness.
Advertisement
Pharmacy Times spoke with holistic oncology pharmacist Jenna Carmichael from Wobbly Arrow Wellness about how she started in this specific industry and how she helps her patients navigate the ups and downs of cancer treatments.
Advertisement
Related to this article
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
2
Understanding Kratom: Pharmacology, Safety, and Regulation
3
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
4
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
5